122 related articles for article (PubMed ID: 21902499)
1. Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms.
Tzvetkov MV; Behrens G; O'Brien VP; Hohloch K; Brockmöller J; Benöhr P
Pharmacogenomics; 2011 Oct; 12(10):1417-27. PubMed ID: 21902499
[TBL] [Abstract][Full Text] [Related]
2. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
[TBL] [Abstract][Full Text] [Related]
3. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
4. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
Chen S; Huo X; Lin Y; Ban H; Lin Y; Li W; Zhang B; Au WW; Xu X
Int J Hyg Environ Health; 2010 Mar; 213(2):140-5. PubMed ID: 20189873
[TBL] [Abstract][Full Text] [Related]
5. Outcome Definition Influences the Relationship Between Genetic Polymorphisms of
Zazuli Z; Otten LS; Drögemöller BI; Medeiros M; Monzon JG; Wright GEB; Kollmannsberger CK; Bedard PL; Chen Z; Gelmon KA; McGoldrick N; Kitchlu A; Vijverberg SJH; Masereeuw R; Ross CJD; Liu G; Carleton BC; Maitland-van der Zee AH
Genes (Basel); 2019 May; 10(5):. PubMed ID: 31083486
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.
Chen C; Wang F; Wang Z; Li C; Luo H; Liang Y; An X; Shao J; Li Y
Cancer Chemother Pharmacol; 2013 Aug; 72(2):315-22. PubMed ID: 23712330
[TBL] [Abstract][Full Text] [Related]
7. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Hinai Y; Motoyama S; Niioka T; Miura M
J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
[TBL] [Abstract][Full Text] [Related]
8. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
9. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer.
Zhou W; Liu G; Park S; Wang Z; Wain JC; Lynch TJ; Su L; Christiani DC
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):491-6. PubMed ID: 15734977
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.
Su D; Ma S; Liu P; Jiang Z; Lv W; Zhang Y; Deng Q; Smith S; Yu H
Lung Cancer; 2007 May; 56(2):281-8. PubMed ID: 17222938
[TBL] [Abstract][Full Text] [Related]
11. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
Goekkurt E; Al-Batran SE; Hartmann JT; Mogck U; Schuch G; Kramer M; Jaeger E; Bokemeyer C; Ehninger G; Stoehlmacher J
J Clin Oncol; 2009 Jun; 27(17):2863-73. PubMed ID: 19332728
[TBL] [Abstract][Full Text] [Related]
13. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma.
Wang Y; Chen J; Li X; He Y; Hu B; Ji C; Xu J
Oncol Rep; 2011 Apr; 25(4):1047-52. PubMed ID: 21286668
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of DNA repair genes: ERCC1 G19007A and ERCC2/XPD C22541A in a northeastern Chinese population.
Yin J; Li J; Vogel U; Wang H
Biochem Genet; 2005 Oct; 43(9-10):543-8. PubMed ID: 16341770
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in ERCC1 and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population.
Wang SL; Zhao H; Zhou B; Chen YL; Zou Y; Zhu XF; Li QS; Han MZ; Yang RC; Han ZC
Leuk Res; 2006 Nov; 30(11):1341-5. PubMed ID: 16723154
[TBL] [Abstract][Full Text] [Related]
17. Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study.
Nikitas N; Karadimou A; Tsitoura E; Soupos N; Tsiatas M; Karavasilis V; Pectasides D; Pavlidis N; Chrisofos M; Adamakis I; Murray S; Fountzilas G; Dimopoulos MA; Bamias A
Pharmacogenomics; 2012 Nov; 13(14):1595-607. PubMed ID: 23148636
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients.
Khrunin AV; Moisseev A; Gorbunova V; Limborska S
Pharmacogenomics J; 2010 Feb; 10(1):54-61. PubMed ID: 19786980
[TBL] [Abstract][Full Text] [Related]
19. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
Stocker G; Ott K; Henningsen N; Becker K; Hapfelmeier A; Lordick F; Hois S; Plaschke S; Höfler H; Keller G
Eur J Cancer; 2009 Dec; 45(18):3326-35. PubMed ID: 19822419
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
Park DJ; Zhang W; Stoehlmacher J; Tsao-Wei D; Groshen S; Gil J; Yun J; Sones E; Mallik N; Lenz HJ
Clin Adv Hematol Oncol; 2003 Mar; 1(3):162-6. PubMed ID: 16224397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
